文献速递心力衰竭与心肌病

射血分数轻度降低或保留的心衰住院患者中SGLT2i的早期应用

Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
PubMed 文献 · JAMA Cardiol · 2025-01-01

IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%.…

要点

  • LVEF>40%心衰住院患者SGLT2i出院处方率两年内从4.2%增至23.5%。
  • LVEF 41%-49%患者处方率(18.5%)高于LVEF≥50%者(13.0%)。
  • 医院间处方率差异显著,中位OR 2.12(95%CI 2.02-2.25)。

核心结论

  • EMPEROR-Preserved试验后两年内,LVEF>40%心衰住院患者SGLT2i出院处方率从4.2%增至23.5%,但医院间差异大。

主要发现

  • 校正患者特征后,医院间处方率变异的中位OR为2.12(95%CI 2.02-2.25)。
  • 在518家年出院≥10例的医院中,11家(2.1%)处方率≥50%,232家(44.8%)处方率<10%。

临床怎么用

  • 对于LVEF>40%的心衰住院患者,应考虑在出院时处方SGLT2i以改善临床结局。
  • 需关注医院间处方率差异,促进指南推荐疗法的均衡应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are the first therapy shown to improve clinical outcomes for patients with heart failure (HF) and a left ventricular ejection fraction (LVEF) greater than 40%. Nationwide adoption of SGLT2is in the US since publication of the Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Preserved Ejection Fraction (EMPEROR-Preserved) in August 2021 is unknown. OBJECTIVE: To examine trends and hospital-level variation in SGLT2i adoption. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included patients with LVEF greater than 40% who were hospitalized for decompensated HF at 1 of 557 sites in the US between July 1, 2021, and September 30, 2023, from the Get With The Guidelines-Heart Failure registry. MAIN OUTCOMES AND MEASURES: Patient-level trends and site-level variation in prescription rates of SGLT2i at hospital discharge. Site-level variation was quantified using the median odds ratio, which describes the average odds that a patient being treated at one vs another randomly selected hospital would receive SGLT2i therapy at discharge. RESULTS: Of 158 849 patients (median [IQR] age, 76 [66-85] years; 89 816 females [56.5%]), 22 126 eligible patients (13.9%) with HF and an LVEF greater than 40% were prescribed an SGLT2i at hospital discharge. Quarterly prescription rates increased from 4.2% in July to September 2021 to 23.5% in July to September 2023 (P for trend < .001). SGLT2i prescription was more likely among patients with HF with mildly reduced LVEF (41%-49%) than in those with preserved LVEF (≥50%; 5127 of 27 712 patients [18.5%] vs 16 999 of 131 137 patients [13.0%]; absolute standardized difference, 16.7%). After adjustment for patient characteristics, there was a high variance between hospitals in the rate of SGLT2i prescription (median odds ratio, 2.12; 95% CI, 2.02-2.25). Among 518 hospitals with 10 or more eligible discharges, 11 hospitals (2.1%) discharged 50% or more of their patients with an SGLT2i prescription, while 232 (44.8%) discharged fewer than 10% of eligible patients with an SGLT2i prescription. CONCLUSION AND RELEVANCE: For patients with HF and an LVEF greater than 40%, discharge prescription of SGLT2is increased from 4.2% to 23.5% during the first 2 years after the EMPEROR-Preserved trial demonstrating treatment benefits; however, these rates varied across US hospitals.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Abdel Jawad M, Spertus JA, Ikeaba U, et al. Early Adoption of Sodium-Glucose Cotransporter-2 Inhibitor in Patients Hospitalized With Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025. PMID: 39556474. doi:10.1001/jamacardio.2024.4489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。